EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects

JungJin Oh iD, Eunsol Yang, In-Jin Jang, Hyejung Lee iD, Hokyun Yoo iD, Jae-Yong Chung, SeungHwan Lee, Jaeseong Oh iD

Pharmaceutics · 07.02.2023 · 15 (2) · 549

DOI: 10.3390/pharmaceutics15020549 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 07.02.2023. Verfasst von JungJin Oh und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul 03080, Republic of Korea. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Daewoong Pharmaceutical (South Korea), Daewoong Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acid-reducing agents are commonly used for the prevention of aspirin-induced gastrointestinal complications such as peptic ulcers. As a novel potassium-competitive acid blocker, fexuprazan is expected to prevent aspirin-induced gastrointestinal complications. This randomized, open-label study aimed to evaluate the pharmacodynamic and pharmacokinetic interactions between aspirin and fexuprazan in healthy Koreans. Subjects randomized to the aspirin group received 500 mg aspirin in combination with 80 mg fexuprazan. For the fexuprazan group, fexuprazan 80 mg was administered alone and then in combination with aspirin 500 mg. Platelet aggregation inhibited by aspirin and the pharmacokinetic parameters of aspirin and fexuprazan were compared between monotherapy and combination therapy. A total of 22 subjects completed the study. The platelet aggregation-inhibitory activity and systemic exposure to aspirin were not significantly affected by fexuprazan coadministration. The systemic exposure of fexuprazan was decreased up to 20% by aspirin coadministration, which was not regarded as clinically meaningful considering the previously reported exposure–response relationship. In conclusion, there were no clinically relevant pharmacodynamic or pharmacokinetic interactions between aspirin and fexuprazan. This finding suggests the potential of fexuprazan for the prevention of aspirin-induced gastrointestinal complications, serving as a baseline for optimizing its therapeutic application with aspirin.

Schlagwörter

Stichwörter der Autor:innen

aspirindrug interactionsfexuprazangastrointestinal complicationspotassium-competitive acid blocker

Autor:innen und Institutionen

  • Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul 03080, Republic of Korea.
  • Medical Research Center, Seoul National University, Seoul 03080, Republic of Korea.
  • Daewoong Pharmaceutical Co., Ltd., Seoul 06170, Republic of Korea.
  • Department of Clinical Pharmacology and Therapeutics, Seoul National University Bundang Hospital, Seongnam 13620, Republic of Korea.

ORCID-Profile: JungJin Oh, Hyejung Lee, Hokyun Yoo, Jaeseong Oh

Förderung

  • Daewoong Pharmaceutical (South Korea)
  • Daewoong Pharmaceutical Co., Ltd.

Zitieren

APA

Oh, J., Yang, E., Jang, I. J., Lee, H., Yoo, H., Chung, J. Y., Lee, S., & Oh, J. (2023). Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects. Pharmaceutics, 15(2), 549. https://doi.org/10.3390/pharmaceutics15020549

Vancouver

Oh J, Yang E, Jang IJ, Lee H, Yoo H, Chung JY, et al. Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects. Pharmaceutics. 2023;15(2):549. doi:10.3390/pharmaceutics15020549

BibTeX
@article{Oh2023,
  author = {Oh, JungJin and Yang, Eunsol and Jang, In-Jin and Lee, Hyejung and Yoo, Hokyun and Chung, Jae-Yong and Lee, SeungHwan and Oh, Jaeseong},
  title = {Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects},
  journal = {Pharmaceutics},
  year = {2023},
  volume = {15},
  number = {2},
  pages = {549},
  doi = {10.3390/pharmaceutics15020549}
}
Kostenlos starten →